PDZK1IP1 and adenocarcinoma: In addition, we provide evidence that MAP17 levels predict sensitivity to therapies currently under clinical use, including platinum-based compounds and EGFR inhibitors, and that treatment with proteasome inhibitors, especially bortezomib, may be a novel therapeutic approach for MAP17-overexpressing adenocarcinomas.